DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by investment analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage presently has a $75.00 price target on the medical instruments supplier’s stock. J P Morgan Chase & Co’s target price would indicate a potential upside of 13.53% from the stock’s previous close.

A number of other research analysts have also recently weighed in on XRAY. HC Wainwright reiterated a “hold” rating and issued a $68.00 target price on shares of DENTSPLY SIRONA in a report on Thursday, December 7th. BidaskClub lowered DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Stephens assumed coverage on DENTSPLY SIRONA in a research report on Tuesday, November 28th. They issued an “overweight” rating and a $75.00 price objective on the stock. Jefferies Group cut their price objective on DENTSPLY SIRONA from $72.00 to $66.00 and set a “buy” rating on the stock in a research report on Wednesday, August 23rd. Finally, Zacks Investment Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 12th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $69.31.

DENTSPLY SIRONA (NASDAQ XRAY) traded up $1.07 during mid-day trading on Wednesday, hitting $66.06. The stock had a trading volume of 1,624,596 shares, compared to its average volume of 1,650,827. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $68.98. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $15,240.00, a PE ratio of 25.90, a price-to-earnings-growth ratio of 2.58 and a beta of 1.31.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. During the same quarter last year, the firm earned $0.66 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. sell-side analysts forecast that DENTSPLY SIRONA will post 2.65 EPS for the current year.

In other DENTSPLY SIRONA news, insider Mark Thierer bought 77,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were acquired at an average cost of $66.04 per share, with a total value of $5,085,080.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Nicholas W. Alexos bought 50,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were acquired at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The disclosure for this purchase can be found here. 1.99% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Veritas Asset Management LLP increased its position in shares of DENTSPLY SIRONA by 2.6% during the second quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after acquiring an additional 157,616 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in shares of DENTSPLY SIRONA by 78.7% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock worth $771,000 after acquiring an additional 5,236 shares during the last quarter. Royce & Associates LP increased its position in shares of DENTSPLY SIRONA by 23.4% during the second quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock worth $8,212,000 after acquiring an additional 24,000 shares during the last quarter. Delta Lloyd Asset Management N.V. purchased a new stake in shares of DENTSPLY SIRONA during the second quarter worth about $15,624,000. Finally, Grandfield & Dodd LLC grew its stake in DENTSPLY SIRONA by 1.8% in the third quarter. Grandfield & Dodd LLC now owns 236,109 shares of the medical instruments supplier’s stock worth $14,122,000 after purchasing an additional 4,140 shares in the last quarter. 96.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “J P Morgan Chase & Co Upgrades DENTSPLY SIRONA (XRAY) to “Overweight”” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/13/j-p-morgan-chase-co-upgrades-dentsply-sirona-xray-to-overweight.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.